Manguoglu, E., Akdeniz, S., Dündar, N., Duman, Ö., Aktekin, B., Haspolat, Ş., Lüleci, G., Manguoglu, E., Akdeniz, S., Dündar, N., Duman, Ö., Aktekin, B., Haspolat, Ş., Lüleci, G., and Yeditepe Üniversitesi
Approximately 30% of epileptic patients remain untreated, in spite of trials with maximum tolerable doses of more than one drug. The RalA binding protein 1 (RALBP1/RLIP76), a multifunctional, anti-apoptotic, multidrug transporter protein, has been proposed as being responsible for the drug resistance mechanism in epilepsy. We have investigated polymorphic differences in the coding regions and exon-intron boundaries of the RLIP76 gene, between 146 refractory and 155 non refractory epileptic patients in Turkey, using denaturing high performance liquid chromatography (HPLC) and sequencing analysis techniques. We have detected the following sequence variants: c.160-4G>A, c.187C>G, c.1562-38G>A, c.1670+107G>A, c.1670+93G>A, c.1670+96G>A, c.1670+100C>T, c.1670+130C>T, c.1670+131G>C, c.1670+140 G>C, and found no statistically significant correlation between allele frequencies and drug response status. We conclude that sequence variants of this gene are not involved in drug resistance in epilepsy. Akdeniz Üniversitesi: 2006.01.0103.010 This study was supported by the Akdeniz University Scientific Research Projects Foundation and Coordination Unit Project number: 2006.01.0103.010 (EM).